Key Highlights

  • EPS was USD 0.30 against an estimated loss of USD 0.02, while Revenue of USD 0.299 million missed estimates.
  • Net income was USD 59.1 million, compared with a net loss of USD 7.7 million a year earlier.
  • Cash, equivalents and marketable securities were USD 337.5 million, and a share repurchase settled on October 5, 2026.
  • The filing details a settlement with Moderna and pending Patent cases against Pfizer and BioNTech.

Arbutus Biopharma (NASDAQ:ABUS) reported third quarter 2026 Earnings Per Share of USD 0.30, against an estimated loss of USD 0.02. Revenue of USD 0.299 million fell short of the USD 1.00 million estimate. Net Income was USD 59.1 million, compared with a net loss of USD 7.7 million a year earlier, and USD 223.7 million for the nine months against a net loss of USD 29.7 million.

Research and development expenses decreased USD 3.2 million in the quarter and USD 10.6 million for the nine months compared with the same periods of 2025. Accrued restructuring costs were USD 0.1 million at September 30.

Moderna Settlement Terms as Described in the Filing

The quarterly filing describes a settlement with Moderna. Under the agreement, Moderna made an aggregate USD 950.0 million noncontingent lump sum payment to the company and its partner Genevant in July 2026. The company received USD 178.4 million as its share, which included reimbursement of litigation costs. Moderna is also obligated to pay an additional aggregate contingent lump sum of USD 1.3 billion upon a ruling favorable to the company and Genevant in a limited appeal Moderna filed related to 28 U.S.C. §1498.

The contingent payment depends on the outcome of that appeal, and no amount can be assumed until a ruling is issued.

In April 2023 the company and Genevant filed a lawsuit in the District of New Jersey against Pfizer and BioNTech, alleging infringement of five United States patents in the manufacture and sale of COVID-19 vaccines. The filing states the court issued a claim construction ruling in September 2025 that the company generally considers favorable. Fact discovery is ongoing, a final pretrial conference is scheduled for November 2027, and the parties are awaiting a trial date.

In July 2026 and November 2026 the company and Genevant filed multiple international suits against Pfizer, BioNTech and certain affiliates in Canada, before the Unified Patent Court and in Japan, seeking injunctions and monetary relief. These are allegations in court filings, and the defendants' positions are described in their own filings.

Capital and Cash

Cash and cash equivalents were USD 264.2 million and marketable securities USD 73.3 million at September 30, together USD 337.5 million, compared with USD 18.0 million and USD 73.5 million at December 31, 2025. Equity records an obligation to repurchase shares of USD 237.9 million including transaction costs. The filing states the repurchase was funded with available cash and settled on October 5, 2026, including cancellation of the purchased shares.

Items to Follow

The ruling in Moderna's limited appeal, the scheduling of the Pfizer and BioNTech trial, activity in the international cases and spending after the share repurchase are the items to follow.